Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation.
3-Thia fatty acids are modified fatty acids that promote hepatic peroxisome proliferation and decrease serum triacylglycerol, cholesterol and free fatty acid levels in rats. In vivo administration of tetradecylthioacetic acid (TTA) to rats led to a significant decrease in liver apolipoproteins apoA-I, A-II, A-IV, and C-III mRNA levels, and to an increase of liver acyl-CoA oxidase (ACO), carnitine palmitoyltransferase-II, and 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMG-CoA synthase) mRNA levels and activities. By contrast, no significant changes of lipoprotein lipase (LPL) mRNA levels were detected in rat epididymal adipose tissue. Liver carnitine palmitoyltransferase-I, apoB, apoE, and LDL receptor mRNA levels were not significantly affected. When tested in vitro, TTA increased rat ACO and carnitine palmitoyltransferase-I mRNA levels in primary rat hepatocytes and also LPL mRNA levels in 3T3-L1 preadipocytes. TTA also enhanced the transcriptional activity of chimeras containing the DNA binding domain of the yeast transcription factor Gal4 fused to the ligand binding domain of either human PPARalpha or human PPARgamma. The effect depended on the concentration tested and the cell type. In conclusion, our data suggest that in vitro, TTA activates both PPARalpha and PPARgamma, but the latter with much lower affinity. TTA affects serum lipid levels in vivo in rats by acting mainly on the liver via PPARalpha where it decreases the liver expression of genes involved in vascular lipid transport and increases the expression of genes involved in intracellular fatty acid metabolism. -Raspé, E., L. Madsen, A-M. Lefebvre, I. Leitersdorf, L. Gelman, J. Peinado-Onsurbe, J. Dallongeville, J-C. Fruchart, R. Berge, and B. Staels. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation.
Raspé
E
E
U325, INSERM, Département d'Athérosclérose/U325 INSERM, Institut Pasteur de Lille, 59019 Lille, France.
Madsen
L
L
Lefebvre
A M
AM
Leitersdorf
I
I
Gelman
L
L
Peinado-Onsurbe
J
J
Dallongeville
J
J
Fruchart
J C
JC
Berge
R
R
Staels
B
B
D016475:3T3 Cells; D000273:Adipose Tissue / Q000737:chemistry / Q000378:metabolism; D000818:Animals; D001053:Apolipoproteins / Q000235:genetics*; D002478:Cells, Cultured; D005227:Fatty Acids; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000737:chemistry / Q000166:cytology / Q000378:metabolism*; D008297:Male; D051379:Mice; D020033:Protein Isoforms / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*; D013440:Sulfides / Q000494:pharmacology*; D014157:Transcription Factors / Q000502:physiology*; D014407:Tumor Cells, Cultured
D001053:Apolipoproteins; D005227:Fatty Acids; D008055:Lipids; D020033:Protein Isoforms; D018160:Receptors, Cytoplasmic and Nuclear; D013440:Sulfides; D014157:Transcription Factors; C092156:tetradecylthioacrylic acid; C062078:1-(carboxymethylthio)tetradecane